Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00895830 · ClinicalTrials.gov registry record · Phase 2
Dose-ranging Study of APD405 in Post-operative Nausea and Vomiting (PONV)
A Phase 2 study of Postoperative Nausea and Vomiting, sponsored by Acacia Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 257
- Enrollment target
- 18
- Study locations
NCT00895830: Completed Phase 2 study of Postoperative Nausea and Vomiting, sponsored by Acacia Pharma.
NCT00895830 is a Phase 2 study of Postoperative Nausea and Vomiting that has completed, run by Acacia Pharma. The registered enrollment target is 257 participants, below the 408-participant average among 10 other Postoperative Nausea and Vomiting trials with a reported enrollment target (37% lower). The trial reports 18 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00895830, a Phase 2 study of Postoperative Nausea and Vomiting, has completed, sponsored by Acacia Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 257 participants
- Enrollment target
- 18
- Study locations
Study Summary
To assess the efficacy and safety of different doses of APD405 in the prevention of post-operative nausea and vomiting (PONV) in adult patients at moderate to high-risk of PONV. Patients must be undergoing elective surgery under general anaesthesia (hysterectomy (any surgical technique), cholecystectomy (any surgical technique) or "other" elective surgery scheduled to last at least one hour from induction of anaesthesia), requiring at least one overnight stay in hospital, and have at least 2 of the following risk factors for PONV: Past history of PONV and/or motion sickness; Non-smoking status; Female gender; Planned opiate use for post-operative analgesia.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG APD405
Study Locations (18)
Other
- University Hospital - Besançon
- Hôpital mère enfant - Bron
- Hôpital Huriez - Lille
- University Hospital - Nancy
- Hôpital FOCH - Paris
- University Hospital - Reims
- Hautepierre Hospital - Strasbourg
- Charité - Universitätsmedizin - Berlin
- Universität Heidelberg - Heidelberg
- University of Leipzig - Leipzig
- Klinikum Ludwigshafen - Ludwigshafen
- Philipps University - Marburg
- University Hospitals of Würzburg - Würzburg
- Geneva University Hospitals - Geneva
- Centre Hospitalier Universitaire Vaudois - Lausanne
California
- UCSF Medical Center at Mt Zion - San Francisco
North Carolina
- Duke University Medical Center - Durham
Texas
- Memorial Hermann-Memorial City Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 257 participants |
| Start Date | 2009-05 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
What the finished NCT00895830 record still lists
NCT00895830 is an interventional study that assigns participants to a tested intervention. The registered 257 participants enrollment target is mid-sized for trials with a published cap, below the 408-participant average among 10 other Postoperative Nausea and Vomiting trials with a reported enrollment target (37% lower).
The record links to 1 condition, with Postoperative Nausea and Vomiting appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00895830 lists 18 locations in 4 states (Other, California, North Carolina).
Frequently Asked Questions
What is clinical trial NCT00895830 about?
NCT00895830 is a clinical study titled "Dose-ranging Study of APD405 in Post-operative Nausea and Vomiting (PONV)". To assess the efficacy and safety of different doses of APD405 in the prevention of post-operative nausea and vomiting (PONV) in adult patients at moderate to high-risk of PONV. Patients must be undergoing elective surgery under general anaesthesia (hysterectomy (any surgical technique), cholecystec...
What is the current status of trial NCT00895830?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 257 participants. The study started on 2009-05. Estimated completion is 2009-11.
What conditions does trial NCT00895830 study?
This clinical trial studies the following conditions: Postoperative Nausea and Vomiting.
What interventions are being tested in trial NCT00895830?
The interventions under investigation include: Placebo (DRUG), APD405 (DRUG).
Who is sponsoring clinical trial NCT00895830?
This trial is sponsored by Acacia Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00895830 being conducted?
This trial has 18 study locations across California, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postoperative Nausea and Vomiting
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00895830's enrollment target sits among peer trials
257 4th of 10 higher than 7 of 10 other Postoperative Nausea and Vomiting trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Postoperative Nausea and Vomiting trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Preoperative Use of Pantoprazole for Prevention of Post Operative Nausea and Vomiting in Gynecologic Surgery
RECRUITING · Phase 2
-
Use of Transcutaneous Electrical Nerve Stimulation Device, Reletex Reliefband, With Current ERAS (Enhanced Recovery After Surgery) Protocol to Further Decrease Postoperative Nausea and Vomiting in the Bariatric Surgical Patient Within the First 24 Hours Postoperatively.
RECRUITING · NA
-
A Pilot Study to Evaluate Barhemsys for the Prevention of Postoperative Nausea and Vomiting in the Bariatric Surgery Population
RECRUITING · Phase 3
-
Costs of Postoperative Nausea and Vomiting in Ambulatory Surgery Patients
COMPLETED
-
Clinical Use of Baxter Animated Retching Faces (BARF) Scale in Children
COMPLETED
-
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03618550 · 257 participants · Phase 2
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
- NCT04674267 · 257 participants · NA
Resilience and Equity in Aging, Cancer, and Health (REACH)
- NCT06099288 · 257 participants · NA
Strong Families Start at Home/Familias Fuertes Comienzan en Casa
- NCT06207084 · 257 participants · NA
The Fit With Us Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia